cells

Board of Directors

Kathryn Falberg

Kathryn Falberg

Ms. Falberg has served as a member of the Arcus board since September 2017. Previously she served as EVP and CFO of Jazz Pharmaceuticals and was responsible for strategy, corporate development, corporate communications, and information technology.

arrow
Juan Jaen

Juan Jaen, PhD

President

Dr. Jaen has been engaged in all aspects of drug discovery and development for more than 30 years, and in 2015 he co-founded Arcus. Before starting Arcus, Dr. Jaen was co-founder and President of Flexus Biosciences. He was Chief Scientific Officer and SVP of Drug Discovery at ChemoCentryx for 7 years,

arrow
Jennifer Jarrett

Jennifer Jarrett

Ms. Jarrett previously served as the CFO and COO of Arcus and has continued to work with the company as a member of the board since January 2019. She is currently the VP of Corporate Development and Capital Markets at Uber and is responsible for their M&A and capital markets activities.

arrow
Yasunori Kaneko

Yasunori Kaneko, MD

Dr. Kaneko has served as a member of the Arcus board since May 2015. He is currently the Managing Director at Skyline Venture Partners and was previously the CFO and VP, Business Development at Tularik. Dr. Kaneko has also served as SVP and CFO of Ionis Pharmaceuticals.

arrow
David Lacey

David Lacey, MD

Dr. Lacey has had a distinguished academic and highly accomplished biopharmaceutical industry career discovering and creating life-changing and critical quality of life improvement therapies for patients.

arrow
Patrick Machado

Patrick Machado, JD

Mr. Machado has served as a member of the Arcus board since December 2019. He has more than 20 years of experience growing biopharmaceutical organizations from development through commercialization. He co-founded and served as CFO and CBO at Medivation until his retirement and served as a member of Medivation’s Board of Directors

arrow
Merdad Parsey

Merdad Parsey, MD, PhD

Dr. Parsey is currently the Chief Medical Officer of Gilead Sciences, where he is responsible for overseeing Gilead’s global clinical development and medical affairs organizations. Prior to joining Gilead, Dr. Parsey served as Senior Vice President of Early Clinical Development at Genentech, where he led clinical development for areas including

arrow
Antoni Ribas

Antoni Ribas, MD, PhD

Dr. Ribas is an internationally recognized physician-scientist who conducts translational and clinical research to understand how the immune system can be used to treat cancer. He has been a leader in the research and clinical development of multiple types of therapeutic agents, including immune checkpoint inhibitors, gene-engineered

arrow
Terry Rosen

Terry Rosen, PhD

Chief Executive Officer

Dr. Rosen has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for more than 30 years. In 2015, he co-founded Arcus, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression. Previously, Dr. Rosen was co-founder and CEO of Flexus Biosciences,

arrow